Financials Oculis Holding AG

Equities

OCS

CH1242303498

Biotechnology & Medical Research

End-of-day quote Nasdaq 18:00:00 2024-06-24 EDT 5-day change 1st Jan Change
11.82 USD -0.30% Intraday chart for Oculis Holding AG +0.64% +5.30%

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 153.1 345.7 441.4 - -
Enterprise Value (EV) 1 153.1 254 313.4 416.3 448.1
P/E ratio -0.72 x -3.18 x -6.24 x -5.53 x -5.27 x
Yield - - - - -
Capitalization / Revenue - 391 x 480 x 42.2 x 13.1 x
EV / Revenue - 288 x 341 x 39.8 x 13.3 x
EV / EBITDA - -3.16 x -5.69 x -11 x 59 x
EV / FCF - -4,681,856 x - - -
FCF Yield - -0% - - -
Price to Book - 3.69 x 3.44 x 4.82 x 4.5 x
Nbr of stocks (in thousands) 16,399 36,598 41,740 - -
Reference price 2 9.336 9.445 10.58 10.58 10.58
Announcement Date 3/28/23 3/18/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 0.883 0.9197 10.46 33.71
EBITDA 1 - -80.43 -55.06 -37.74 7.594
EBIT 1 - -80.71 -59.65 -61.09 -27.88
Operating Margin - -9,140.88% -6,485.66% -583.86% -82.71%
Earnings before Tax (EBT) 1 - -88.7 -59.77 -68.06 -63.96
Net income 1 -38.7 -88.8 -61.56 -72.08 -79.06
Net margin - -10,056.85% -6,693.95% -688.85% -234.57%
EPS 2 -12.94 -2.970 -1.696 -1.911 -2.006
Free Cash Flow - -54.26 - - -
FCF margin - -6,144.85% - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 - - - - -
Announcement Date 3/28/23 3/18/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 0.25 - 0.219 0.185 0.222 0.2503 0.2451 0.2226 0.2 0.2
EBITDA - - -12.89 -12.11 - - - - - -
EBIT 1 -10.74 - -12.96 -12.18 -15.33 -15.26 -15.28 -16.07 - -
Operating Margin -4,298% - -5,917.35% -6,585.95% -6,904.5% -6,098.17% -6,232.87% -7,218.8% - -
Earnings before Tax (EBT) 1 -12.76 - -17.53 -12.51 -16.06 -15.46 -15.5 -15.53 - -
Net income 1 -12.88 - -17.41 -12.5 -16.09 -15.17 -15.4 -15.88 - -
Net margin -5,150.8% - -7,951.14% -6,756.22% -7,249.1% -6,062.99% -6,281.18% -7,133.32% - -
EPS 2 -0.3800 -2.530 -0.4800 -0.3400 -0.4400 -0.4093 -0.4264 -0.4435 -0.3700 -0.3700
Dividend per Share - - - - - - - - - -
Announcement Date 8/29/23 8/29/23 11/15/23 3/18/24 5/8/24 - - - - -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - 6.69
Net Cash position 1 - 91.7 128 25.1 -
Leverage (Debt/EBITDA) - - - - 0.8805 x
Free Cash Flow - -54.3 - - -
ROE (net income / shareholders' equity) - - -49.1% - 6.86%
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share 2 - 2.560 3.070 2.190 2.350
Cash Flow per Share 2 - -1.800 -1.990 -2.470 -
Capex - 0.05 - - -
Capex / Sales - 5.44% - - -
Announcement Date 3/28/23 3/18/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.58 CHF
Average target price
25.97 CHF
Spread / Average Target
+145.53%
Consensus
  1. Stock Market
  2. Equities
  3. OCS Stock
  4. Financials Oculis Holding AG